pembrolizumab

Details

Files
Generic Name:
pembrolizumab
Project Status:
Active
Therapeutic Area:
Advanced or metastatic malignant pleural mesothelioma
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0387-000
Call for patient/clinician input closed:
Tumour Type:
Other
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Keytruda in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult and pediatric (12 years and older) patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
​Keytruda in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult and pediatric (12 years and older) patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open17-Oct-24
Call for patient/clinician input closed06-Dec-24
Submission received27-Nov-24
Submission accepted11-Dec-24
Review initiated12-Dec-24
Draft CADTH review report(s) provided to sponsor for comment26-Mar-25
Deadline for sponsors comments04-Apr-25
CADTH review report(s) and responses to comments provided to sponsor02-May-25
Expert committee meeting (initial)14-May-25
Draft recommendation issued to sponsorMay 27, 2025
To
May 29, 2025
Draft recommendation posted for stakeholder feedback05-Jun-25
End of feedback period19-Jun-25